MX2013007543A - Composicion farmaceutica conteniendo l-adn. - Google Patents

Composicion farmaceutica conteniendo l-adn.

Info

Publication number
MX2013007543A
MX2013007543A MX2013007543A MX2013007543A MX2013007543A MX 2013007543 A MX2013007543 A MX 2013007543A MX 2013007543 A MX2013007543 A MX 2013007543A MX 2013007543 A MX2013007543 A MX 2013007543A MX 2013007543 A MX2013007543 A MX 2013007543A
Authority
MX
Mexico
Prior art keywords
dna
rna
pharmaceutical composition
composition containing
cleave
Prior art date
Application number
MX2013007543A
Other languages
English (en)
Inventor
Volker A Erdmann
Original Assignee
Volker A Erdmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volker A Erdmann filed Critical Volker A Erdmann
Publication of MX2013007543A publication Critical patent/MX2013007543A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con el uso de un L-ADN capaz de la ligaen un L-ARN, en particular en una reacción a contrasentido, y opcionalmente capaz de separar el L-ARN en le región de una secuencia meta del L-ARN, para la producción de una composición farmacéutica para el tratamiento de reacciones fisiológicas secundarias indeseables a causa de la administración de una molécula terapéutica conteniendo L-ARN. El L-ADN puede alternativamente usarse, sin embargo, también para seaprar un ARN o ADN meta.
MX2013007543A 2010-12-31 2012-01-02 Composicion farmaceutica conteniendo l-adn. MX2013007543A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010056610A DE102010056610A1 (de) 2010-12-31 2010-12-31 Pharmazeutische Zusammensetzung enthaltend L-DNA
PCT/DE2012/000008 WO2012089207A2 (de) 2010-12-31 2012-01-02 Pharmazeutische zusammensetzung enthaltend l-dna

Publications (1)

Publication Number Publication Date
MX2013007543A true MX2013007543A (es) 2014-04-30

Family

ID=45999500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007543A MX2013007543A (es) 2010-12-31 2012-01-02 Composicion farmaceutica conteniendo l-adn.

Country Status (12)

Country Link
US (1) US20130345290A1 (es)
EP (1) EP2668275A2 (es)
JP (1) JP2014504589A (es)
KR (1) KR20140043052A (es)
CN (1) CN103492571A (es)
AU (1) AU2012203994A1 (es)
BR (1) BR112013017001A2 (es)
CA (1) CA2850863A1 (es)
DE (1) DE102010056610A1 (es)
MX (1) MX2013007543A (es)
RU (1) RU2013135647A (es)
WO (1) WO2012089207A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
US9983565B2 (en) * 2015-03-27 2018-05-29 Intel Corporation Technologies for bio-chemically controlling operation of a machine
CN105274196A (zh) * 2015-04-01 2016-01-27 湖南大学 一种基于l型脱氧核酶生物体系中金属离子的检测试剂盒、检测方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59708838D1 (de) * 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
DE19800899A1 (de) * 1998-01-13 1999-07-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Oligoliganden mit Bindungsvermögen etc.
DE10020275A1 (de) * 2000-04-25 2001-10-31 Manfred Schneider Enantiomere Bausteine der 2-Deoxy-L-Ribose und 2-Deoxy-D-Ribose, Verfahren zu ihrer Herstellung sowie Verwendung zur Synthese von natürlichen und nicht natürliche L- und D-Nucleinsäuren, L- und D- konfigurierten Oligonucleotiden, L- und D-konfigurierter DNA und davon abgeleiteten pharmazeutischen Wirkstoffen
ATE452655T1 (de) * 2001-06-10 2010-01-15 Noxxon Pharma Ag Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung
US20030219422A1 (en) * 2001-11-15 2003-11-27 Noxxon Pharma Ag Allosteric ribozymes and uses thereof
US7101991B2 (en) * 2002-10-02 2006-09-05 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
DE10346487A1 (de) * 2003-10-02 2005-05-12 Transmit Technologietransfer Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
CN101217967B (zh) * 2005-05-04 2014-09-10 诺松制药股份公司 镜像异构体的新用途
EP2111449B1 (en) 2007-01-16 2012-03-07 Yissum Research Development Company of the Hebrew University of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
EP2393504B1 (de) 2009-02-06 2013-06-05 Freie Universität Berlin Ein l-ribozym enthaltende pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren

Also Published As

Publication number Publication date
WO2012089207A3 (de) 2012-10-04
CN103492571A (zh) 2014-01-01
DE102010056610A1 (de) 2012-07-05
EP2668275A2 (de) 2013-12-04
RU2013135647A (ru) 2015-02-10
BR112013017001A2 (pt) 2016-09-20
AU2012203994A1 (en) 2013-08-22
JP2014504589A (ja) 2014-02-24
WO2012089207A2 (de) 2012-07-05
KR20140043052A (ko) 2014-04-08
CA2850863A1 (en) 2012-05-07
US20130345290A1 (en) 2013-12-26

Similar Documents

Publication Publication Date Title
WO2014066915A3 (en) Methods and compositions to produce ss-rnai activity with enhanced potency
MX2018012038A (es) Agentes de iarn modificados.
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
MX2015005328A (es) Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
MX2009011878A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina.
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
MX2009003729A (es) Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a.
WO2007117686A3 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
WO2010041913A3 (ko) Grs 단백질 또는 이의 단편의 신규한 용도
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
WO2012078536A3 (en) Double stranded oligonucleotide compounds comprising threose modifications
MX2019007057A (es) Composiciones de adenovirus.
AU2012358181A8 (en) Compositions and methods for the delivery of biologically active RNAs
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
EA201491726A1 (ru) Конъюгаты бороновых кислот олигонуклеотидных аналогов
MX2010006039A (es) Compuestos antagonistas del acido ribonucleico para la modulacion de la expresion de la fosfoinositida-3-cinasa catalitica.
WO2009051659A3 (en) Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
WO2012138708A8 (en) Mhc engagement and clip modulation for the treatment of disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal